Head to head
Retatrutide against Survodutide
A triple agonist against a GLP-1 and glucagon dual. The glucagon arm is the shared part, so the practical question is what adding GIP contributes, and no trial has isolated that by randomising people between these two.
Column A
RetatrutideRetatrutide (triple GLP-1/GIP/glucagon agonist)
An investigational once-weekly triple receptor agonist producing the largest pharmacological weight loss reported to date in trials.
Column B
SurvodutideSurvodutide (GLP-1 / glucagon dual agonist)
An investigational once-weekly GLP-1 and glucagon receptor dual agonist studied for obesity and metabolic liver disease.
Side by side, on the facts we can check
| Attribute | Retatrutide | Survodutide |
|---|---|---|
| Category | Metabolic | Metabolic |
| FDA status | Investigational, not FDA-approved; Phase 3 TRIUMPH-1 reported May 2026; submission expected late 2026 | Investigational, not FDA-approved |
| Half-life | ~6 days | ~6 days |
| Molecular weight | ~4,731 Da | ~4,900 Da |
| Mechanism | Agonizes GLP-1, GIP, and glucagon receptors. The added glucagon activity increases energy expenditure and hepatic fat oxidation, complementing the appetite and insulin effects of the incretin receptors. | Agonizes both GLP-1 and glucagon receptors, combining appetite suppression and improved glucose handling with increased energy expenditure and hepatic fat reduction. |
| Human studies cited | 3 | 3 |
| Legal status, US | Investigational, not approved for any indication | Investigational, not approved |
Frequently asked questions
What is the difference between Retatrutide and Survodutide?
Retatrutide: An investigational once-weekly triple receptor agonist producing the largest pharmacological weight loss reported to date in trials. Survodutide: An investigational once-weekly GLP-1 and glucagon receptor dual agonist studied for obesity and metabolic liver disease.
Which has stronger research evidence, Retatrutide or Survodutide?
This database does not grade compounds. It counts what was run in people: 3 of the 4 studies cited on the Retatrutide profile were human work, against 3 of 3 for Survodutide. Those counts are of our own citation lists and understate any larger literature, and neither is a recommendation.
Are Retatrutide and Survodutide FDA-approved?
Retatrutide: Investigational, not FDA-approved; Phase 3 TRIUMPH-1 reported May 2026; submission expected late 2026. Survodutide: Investigational, not FDA-approved.
Related posts
Blog articles that cover Retatrutide or Survodutide, newest first.
- Dispatch / Sep 12, 2026 / 8 minDispatch 001: Five Retatrutide Phase 3 Trials Have Finished And None Has Posted Results
- Metabolic / Sep 8, 2026 / 8 minTesofensine Is Not a Peptide: What It Is, the Trials, and the Heart-Rate Issue
- Metabolic / Sep 8, 2026 / 10 minOral GLP-1s in 2026: Wegovy Pill vs Foundayo (Orforglipron) vs Rybelsus, and What Is Coming
- Metabolic / Sep 8, 2026 / 9 minMariTide (Maridebart Cafraglutide): The Once-Monthly GLP-1 Agonist and GIP Blocker, Explained
Reviewed Sep 2026. This page sets two published records side by side. It is educational, it is not medical advice, and it contains no dosing protocols or recommendations for personal use.